INTRODUCTIONPancreatic ductal adenocarcinoma is a highly lethal disease. It is estimated that in 2017 there will be 53 670 new cases and 43 090 deaths in the United States, which now ranks third among cancer related deaths. At the time of diagnosis, roughly 38% of patients have disease which appears to be localized to the pancreas without obvious metastases. Of those patients deemed operable on clinical grounds, 20‐57% are found to have inoperable disease on exploration depending on the extent and nature of preoperative staging. Most patients present with unsuspected metastatic disease, borderline resectable tumors, or locally advanced, unresectable disease owing to involvement of critical vascular structures: superior mesenteric artery (SMA), celiac trunk, common hepatic artery, or superior mesenteric vein (SMV)/portal vein. Despite recent advances in systemic therapy, even those fortunate few who are able to undergo immediate surgery remain largely incurable, with a 5‐year survival of 25‐30% at best.It is clear from these data that two parallel initiatives are essential if we are to improve patient survival. The first is any strategy that will result in an increase in successful R0 resection of the primary tumor and regional nodes (microscopically margin‐negative resection, in which no gross or microscopic tumor remains
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud